ワクチン市場規模：ワクチンタイプ別、対象人口別、流通チャネル別、地域別、2026～2032年

ワクチン市場評価、2026～2032年

2024年のワクチン市場規模は463億米ドルで、予測期間中のCAGRは8.11%で、2032年までに704億米ドルの成長が予測されます。ワクチン市場では、ワクチンで予防可能な病気に対する人々の意識が高まり、公衆衛生が重視されるようになったため、需要が増加しています。COVID-19パンデミックは、伝染病の抑制におけるワクチン接種の必要性を浮き彫りにし、新しいワクチンのさらなる研究開発を促しました。さらに、予防接種プログラムに対する政府の資金援助や支援の増加が、市場の拡大を後押ししています。

さらに、ワクチン接種の需要は感染症だけでなく、がんやその他の慢性疾患の治療用ワクチンにも拡大しています。このような移行は、ワクチン開発および送達技術の技術的進歩とともに、ワクチン市場の今後の成長を支えるものと予測されます。

ワクチン市場定義/概要

ワクチン接種は、特定の感染症に対する獲得免疫を誘導する生物学的製剤です。通常、弱毒化・不活化ウイルスや遺伝物質の断片など、病原体の無害な成分から構成されます。ワクチンが投与されると、免疫系が刺激され、病原体に再び遭遇した場合にそれを認識し攻撃するようになります。ワクチン接種は、疾病を予防し、感染率を低下させ、健康状態によりワクチン接種を受けることができない人々を守る集団免疫力を高める。

ワクチン接種は、弱毒化または不活化された病原体やその遺伝コードの断片など、無害な病原体の構成要素を導入することによって機能します。これにより、将来再びウイルスに遭遇した場合に、免疫系が迅速かつ効率的に反応できるよう準備されます。ワクチン接種は、集団発生を回避し、感染しやすい人々を守り、公衆衛生を向上させるのに役立ちます。

予防接種の未来には、予防接種の効果を高めるために個人の遺伝子プロファイルに合わせて予防接種を行う個別化医療の進歩も含まれます。COVID-19ワクチンで実証されたmRNA技術は、他の感染症やがんの治療にも開発される可能性が高いです。加えて、インフルエンザなどの病気に対する万能ワクチンの製造も試みられており、より高い予防効果が期待されています。

予防ヘルスケアに対する意識の高まりは、ワクチン市場の拡大にどのように貢献しているのか？

予防ヘルスケアへの理解の高まりは、健康管理への積極的なアプローチを促すことで、ワクチンビジネスの拡大に貢献しています。感染症予防におけるワクチン接種の利点について参考資料が増えるにつれ、人々は自分自身や家族のために予防接種を受ける可能性が高くなります。公衆衛生キャンペーンや教育プログラムは、ワクチンと疾病予防の関連性に対する認識を拡大し、その結果、さまざまな集団でワクチンに対する需要が増加しています。このような予防への動向は、人々が自分の健康を優先することを促し、ワクチン接種率の向上と市場拡大につながります。

さらに、予防ヘルスケアの重視により、ワクチンの研究開発に対する政府や企業の投資が増加しています。mRNAワクチンやウイルスベクター・プラットフォームのような新規ワクチン技術への資金提供は、この分野の進歩に拍車をかけています。新しいワクチンが開発され、発表されると、人々の関心が高まり、需要が増加し、ワクチン産業が拡大します。このように予防介入が重視されることで、最終的には感染症の負担が軽減され、公衆衛生全体の成果が向上します。

ワクチン開発コストの高さはワクチン市場成長の抑制要因か？

ワクチン開発コストが高いため、研究・生産に投資できる企業数が制限され、ワクチン事業の拡大が厳しく制限されます。新規ワクチン開発には、広範な研究、臨床試験、規制遵守のための多額の資金投資が必要です。こうしたプロセスには何年もかかり、不確実性も大きいため、中小企業が大手製薬会社と競争するのは難しいです。その結果、新規ワクチンの市場参入が減少し、全体的な成長が鈍化し、顧客の選択肢が狭まる可能性があります。

さらに、ワクチン製造にかかる費用がコストを押し上げ、特に中低所得国でのアクセスが制限される可能性があります。ワクチンの輸送・保管にはコールドチェーンロジスティクスが必要であり、これがコストを上昇させ、流通努力を複雑にしています。このような高コスト構造は、政府やヘルスケアシステムによる包括的な予防接種プログラムの確立を阻害し、感染症対策への取り組みを妨げ、市場の成長の可能性を制限する可能性があります。

目次

第1章 世界のワクチン市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のワクチン市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界のワクチン市場：ワクチンタイプ別

• 概要
• 予防ワクチン
• 治療用ワクチン
• 組み換えワクチン
• 混合ワクチン

第6章 世界のワクチン市場：対象人口別

• 概要
• 小児用ワクチン
• 成人用ワクチン
• 高齢者用ワクチン
• 旅行用予防接種

第7章 世界のワクチン市場：流通チャネル別

• 概要
• 病院および診療所
• 小売薬局
• 政府プログラム
• インターネット薬局

第8章 世界のワクチン市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• GSK plc
• Merck & Co.
• Pfizer Inc.
• Sanofi
• CSL Limited
• Johnson & Johnson Services
• AstraZeneca
• Serum Institute of India Pvt Ltd
• Bharat Biotech International Limited
• Sinovac Biotech Ltd

第11章 付録

• 関連調査

Vaccine Market Valuation - 2026-2032

The vaccine market size was valued at USD 46.3 Billion in 2024 and is projected to grow 70.4 Billion by 2032, exhibiting a CAGR of 8.11% during the forecast period. The vaccine market is witnessing increased demand as people become more aware of vaccine-preventable diseases and place a greater emphasis on public health. The COVID-19 pandemic highlighted the necessity of vaccination in suppressing epidemics, prompting further research and development of new vaccines. Furthermore, increased government funding and support for immunization programs are fuelling market expansion.

Furthermore, vaccination demand is growing beyond infectious disorders to include therapeutic vaccines for cancer and other chronic illnesses. This transition together with technological advances in vaccine development and delivery technologies is projected to support the vaccine market's growth in the years ahead.

Vaccine Market: Definition/ Overview

A vaccination is a biological preparation that induces acquired immunity to a particular infectious disease. It usually comprises a harmless component of the pathogen such as a weakened or inactivated virus or a fragment of its genetic material. When vaccines are delivered, they stimulate the immune system to recognize and attack the pathogen if it is encountered again. Vaccination prevents illnesses, lowers transmission, and adds to herd immunity protecting people who are unable to be vaccinated due to medical conditions.

They function by introducing an innocuous pathogen component such as a weakened or inactivated form or a fragment of its genetic code. This exposure prepares the immune system to respond rapidly and efficiently if the body encounters the virus again in the future. Vaccination helps avoid outbreaks, protects vulnerable populations, and improves public health.

The future of vaccinations includes advances in personalized medicine in which immunizations are tailored to individual genetic profiles for increased efficacy. MRNA technology as demonstrated by COVID-19 vaccines will most likely be developed to treat other infectious diseases and cancer. In addition, attempts are underway to produce universal vaccinations for diseases such as influenza intending to provide greater protection.

How does Growing Awareness of Preventative Healthcare Contribute to the Expansion of the Vaccine Market?

A growing understanding of preventative healthcare helps to expand the vaccine business by encouraging a proactive approach to health management. As people learn more about the benefits of vaccination in preventing infectious diseases, they are more likely to seek immunizations for themselves and their families. Public health campaigns and educational programs have expanded awareness of the link between vaccines and illness prevention, resulting in increased demand for vaccines across various populations. This trend toward prevention encourages people to prioritize their health, which leads to higher vaccination rates and a larger market.

Furthermore, the emphasis on preventative healthcare has resulted in increasing government and corporate sector investment in vaccine research and development. Funding for novel vaccination technologies such as mRNA vaccines and viral vector platforms has spurred progress in this field. As new vaccines are developed and presented, they pique public interest, increasing demand and extending the vaccination industry. This emphasis on prevention interventions eventually reduces the burden of infectious diseases improving overall public health outcomes.

How Does the High Cost of Vaccine Development Serve as a Restraint on the Growth of the Vaccine Market?

The high cost of vaccine development severely limits the expansion of the vaccine business by limiting the number of companies capable of investing in research and production. Developing a novel vaccination necessitates significant financial investment for extensive research, clinical trials, and regulatory compliance. These processes can take years and involve a great deal of uncertainty making it difficult for smaller enterprises to compete with major pharmaceutical giants. As a result, fewer novel vaccines enter the market, potentially slowing overall growth and limiting customer alternatives.

Furthermore, the expense of vaccine manufacture might drive up costs, limiting access, especially in low- and middle-income nations. Transporting and storing vaccines requires cold chain logistics which raises costs and complicates distribution efforts. This high-cost structure may discourage governments and healthcare systems from establishing comprehensive immunization programs hamper efforts to control infectious illnesses, and restrict the market's potential for growth.

Category-Wise Acumens

How do Government Policies and Health Organizations Influence the Uptake of Pediatric Vaccinations?

Pediatric vaccines dominate the vaccine market owing to the increased need for immunization against numerous infectious diseases among children. Measles, mumps, rubella, polio, and hepatitis are all preventable diseases that require vaccination in childhood. Governments and health organizations prioritize kid immunization programs to ensure population health, resulting in broad vaccination campaigns. The implementation of routine vaccination schedules and mandated immunization laws in several countries has increased the demand for pediatric vaccinations.

Furthermore, as parents become more aware of the benefits of vaccinating their children, pediatric vaccinations have grown in popularity. Campaigns highlighting the value of immunization and addressing vaccine hesitancy have increased public trust in vaccination programs. As a result, pharmaceutical companies and healthcare providers are expanding their focus on producing and marketing pediatric vaccinations, resulting in large R&D investments. This emphasis guarantees that pediatric vaccinations remain an important component of the overall vaccine industry.

How do Healthcare Professionals in Hospitals and Clinics Educate Patients about the Benefits and Potential Side Effects of Vaccines?

Hospitals and clinics dominate the vaccine industry because of their critical role in delivering complete healthcare services. These facilities are key places of care for immunizations which are frequently included in ordinary healthcare practices. They provide a controlled environment for immunizations assuring safe storage, handling, and administration. Furthermore, hospitals and clinics frequently have access to a large patient population making it easier to run vaccination programs and campaigns efficiently.

Furthermore, hospitals and clinics are staffed with qualified healthcare experts who can educate people on the benefits of vaccines, address concerns, and manage potential adverse effects. Their established infrastructure facilitates the coordination of immunization schedules, record-keeping, and follow-up care. The emphasis on preventive healthcare in these contexts, particularly in reaction to epidemics or public health campaigns strengthens their position in the vaccine market by assuring high vaccination rates and successful immunization programs.

Country/Region-wise Acumens

How do Strong Research and Development Capabilities Impact the Diversity of Vaccines Available in the North American Region?

North America dominates the vaccination industry owing to its advanced healthcare infrastructure, strong research and development capabilities, and considerable financial investments in biotechnology. The region is home to major pharmaceutical businesses and research organizations that promote innovation and manufacture a diverse range of vaccines. Government support such as funding for vaccine development and public health programs boosts market growth as demonstrated during the COVID-19 pandemic.

Furthermore, North America has a strong distribution network that ensures vaccinations are stored and distributed under optimal circumstances, thereby preserving their potency. Public awareness campaigns and educational tools efficiently communicate the benefits of vaccines which boosts public trust. The region's response to recent health emergencies such as the COVID-19 pandemic, demonstrated its ability to quickly mobilize resources maintaining its leadership in the worldwide vaccination market.

How has the COVID-19 Pandemic Influenced Government Investments in Healthcare Infrastructure and Vaccination Initiatives in the Asia-Pacific Region?

Asia Pacific is the fastest-growing region in the vaccine market owing to a combination of reasons such as increasing population, rising healthcare expenditure, and increased awareness of the benefits of immunization. The region has a vast and diversified population which increases the demand for vaccines to treat a variety of infectious diseases. Furthermore, governments are investing heavily in healthcare infrastructure and vaccination initiatives to improve public health outcomes, particularly considering recent global health disasters such as the COVID-19 pandemic.

Furthermore, the rapid development of biotechnology and pharmaceutical industries in countries such as China and India improved vaccine production capacities and innovation. Collaborations between the public and private sectors accelerate research and development, resulting in the launch of new vaccinations. Furthermore, supporting government policies and initiatives focused on increasing immunization coverage and boosting healthcare access are driving market expansion in the Asia Pacific establishing the region as a worldwide vaccine industry leader.

Competitive Landscape

The Vaccine Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the vaccine market include:

GSK plc, Merck & Co., Pfizer Inc., Sanofi, CSL Limited, Johnson & Johnson Services, AstraZeneca, Serum Institute of India Pvt Ltd, Bharat Biotech International Limited, Sinovac Biotech Ltd.

Latest Developments

• In May 2024, Novavax and Sanofi disclosed a co-exclusive licensing agreement to co-commercialize a COVID-19 vaccine and collaborate on developing novel combination vaccines for COVID-19 and influenza. This strategic partnership allows both companies to leverage their respective expertise and resources to bring innovative vaccine solutions to the market. By joining forces, Novavax and Sanofi aim to enhance their competitive position in the rapidly evolving landscape of vaccine development and distribution.
• In April 2023, Pfizer announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.

Vaccine Market, By Category

• Type of Vaccine:
• Preventive Vaccines
• Therapeutic Vaccines
• Recombinant Vaccines
• Conjugate vaccines
• Target Population:
• Paediatric vaccines
• Adult Vaccines
• Vaccines for the Elderly
• Travel vaccinations
• Channel of Distribution:
• Hospitals and Clinics
• Retail Pharmacies
• Government Programmes
• Internet pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VACCINE MARKET, BY TYPE OF VACCINE

• 5.1 Overview
• 5.2 Preventive Vaccines
• 5.3 Therapeutic Vaccines
• 5.4 Recombinant Vaccines
• 5.5 Conjugate vaccines

6 GLOBAL VACCINE MARKET, BY TARGET POPULATION

• 6.1 Overview
• 6.2 Paediatric vaccines
• 6.3 Adult Vaccines
• 6.4 Vaccines for the Elderly
• 6.5 Travel vaccinations

7 GLOBAL VACCINE MARKET, BY CHANNEL OF DISTRIBUTION

• 7.1 Overview
• 7.2 Hospitals and Clinics
• 7.3 Retail Pharmacies
• 7.4 Government Programmes
• 7.5 Internet pharmacies

8 GLOBAL VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 GSK plc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Merck & Co.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Pfizer Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Sanofi
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 CSL Limited
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Johnson & Johnson Services
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 AstraZeneca
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Serum Institute of India Pvt Ltd
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Bharat Biotech International Limited
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Sinovac Biotech Ltd
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research